What's in Universität des Saarlandes's pipeline?

Universität des Saarlandes has 7 drugs in our index: 0 marketed, 0 filed, 6 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Universität des Saarlandes's portfolio?

Top competitors by shared drug class: Amgen, Assistance Publique - Hôpitaux de Paris, Fondazione Italiana Linfomi - ETS, Hoffmann-La Roche, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universit-t-des-saarlandes.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Universität des Saarlandes — Portfolio Competitive Intelligence Brief

Universität des Saarlandes pipeline: 0 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
R-miniCHOP + Acalabrutinib	R-miniCHOP + Acalabrutinib	phase 3	Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor	CD20 (rituximab component); Bruton tyrosine kinase / BTK (acalabrutinib component)	Oncology
Alternative medications: carboplatin	Alternative medications: carboplatin	phase 3	Platinum-based chemotherapy agent	DNA	Oncology
Conventional Vincristine	Conventional Vincristine	phase 3	Vinca alkaloid	Tubulin	Oncology
optimised rituximab-schedule	optimised rituximab-schedule	phase 3	Monoclonal antibody	CD20	Oncology, Immunology
Ricover-scheme rituximab	Ricover-scheme rituximab	phase 3	Monoclonal antibody (anti-CD20)	CD20	Oncology
R-miniCHOP	R-miniCHOP	phase 3	Monoclonal antibody + chemotherapy combination	CD20	Oncology

Therapeutic area mix

Oncology · 5
Oncology, Immunology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 3 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Fondazione Italiana Linfomi - ETS · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
The Lymphoma Academic Research Organisation · 2 shared drug classes
AryoGen Pharmed Co. · 1 shared drug class
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universität des Saarlandes:

Cite this brief

Drug Landscape (2026). Universität des Saarlandes — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-t-des-saarlandes. Accessed 2026-05-16.